drugset / Trial / NCT00530309
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus
RandomizedParallel-groupTreatment
Summary
A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus
Timeline
- Start
- 2007-08-01
- Primary completion
- 2008-04-17
- Completion
- 2008-04-17
Publications
- Background Seino Y, Nakajima H, Miyahara H, Kurita T, Bush MA, Yang F, Stewart MW. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin. 2009 Dec;25(12):3049-57. doi: 10.1185/03007990903372999.
- Young MA, Wald JA, Matthews JE, Scott R, Hodge RJ, Zhi H, Reinhardt RR. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgrad Med. 2014 Nov;126(7):84-97. doi: 10.3810/pgm.2014.11.2836.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | albiglutide | Peptide | 15 mg | Subcutaneous |
| Subject | albiglutide | Peptide | 30 mg | Subcutaneous |
| Subject | albiglutide | Peptide | 50 mg | Subcutaneous |
| Subject | albiglutide | Peptide | 100 mg | Subcutaneous |